GlSir2.1 of Giardia lamblia is a NAD+-dependent cytoplasmic deacetylase.

The sirtuins are a group of well-conserved proteins widely distributed across all domains of life. These proteins are clustered in the class III of histone deacetylases and are distinctly characterized by their dependence upon NAD+ to carry out the deacetylation of lysine residues in histone proteins (H3 and H4) and non-histones such as the transcription factor p53. The requirement of NAD+ for sirtuin activity makes this group of proteins metabolic sensors, which are favored during caloric stress. Currently, it is known that these proteins are involved in numerous cellular processes that are fundamental for the proper functioning of cells, including control of the cell cycle and cellular survival. In spite of the importance of sirtuins in cell functions, the role that these proteins play in protozoan parasites is not completely understood. In this study, bioinformatic modeling and experimental characterization of the candidate G1Sir2.1 present in the genome of Giardia lamblia were carried out. Consequently, cloning, expression, purification, and in vitro evaluation of the recombinant GlSir2.1 protein's capacity for deacetylation were performed. This allowed for the identification of the NAD+-dependent deacetylase activity of the identified candidate. Production of anti-rHis-GlSir2.1 polyclonal antibodies enabled the observation of a cytoplasmic localization for the endogenous protein in trophozoites, which exhibited a perinuclear aggregation and co-localization with acetylated cytoskeleton structures such as the flagella and median body. Currently, GlSir2.1 is the second sirtuin family member identified in G. lambia, with a demonstrated cytoplasmic localization in the parasite.

Localization and phosphorylation of Plasmodium falciparum nicotinamide/nicotinate mononucleotide adenylyltransferase (PfNMNAT) in intraerythrocytic stages.

BACKGROUND: Nicotinamide adenine dinucleotide (NAD+) is an essential molecule in the energy metabolism of living beings, and it has various cellular functions. The main enzyme in the biosynthesis of this nucleotide is nicotinamide/nicotinate mononucleotide adenylyltransferase (NMNAT, EC 2.7.7.1/18) because it is the convergence point for all known biosynthetic pathways. NMNATs have divergences in both the number of isoforms detected and their distribution, depending on the organism. METHODS: In the laboratory of basic research in biochemistry (LIBBIQ: acronym in Spanish) the NMNATs of protozoan parasites (Leishmania braziliensis, Plasmodium falciparum, Trypanosoma cruzi, and Giardia duodenalis) have been studied, analysing their catalytic properties through the use of proteins. Recombinants and their cellular distribution essentially. In 2014, O'Hara et al. determined the cytoplasmic localization of NMNAT of P. falciparum, using a transgene coupled to GFP, however, the addition of labels to the study protein can modify several of its characteristics, including its sub-cellular localization. RESULTS: This study confirms the cytoplasmic localization of this protein in the parasite through recognition of the endogenous protein in the different stages of the asexual life cycle. Additionally, the study found that PfNMNAT could be a phosphorylation target at serine, tyrosine and threonine residues, and it shows variations during the asexual life cycle. CONCLUSIONS: These experiments confirmed that the parasite is situated in the cytoplasm, fulfilling the required functions of NAD+ in this compartment, the PfNMNAT is regulated in post-transcription processes, and can be regulated by phosphorylation in its residues.

Identification of the nicotinamide mononucleotide adenylyltransferase of Trypanosoma cruzi.

The intracellular parasite Trypanosoma cruzi is the aetiological agent of Chagas disease, a public health concern with an increasing incidence rate. This increase is due, among other reasons, to the parasite's drug resistance mechanisms, which require nicotinamide adenine dinucleotide (NAD+). Furthermore, this molecule is involved in metabolic and intracellular signalling processes necessary for the survival of T. cruzi throughout its life cycle. NAD+biosynthesis is performed by de novo and salvage pathways, which converge on the step that is catalysed by the enzyme nicotinamide mononucleotide adenylyltransferase (NMNAT) (enzyme commission number: 2.7.7.1). The identification of the NMNAT of T. cruzi is important for the development of future therapeutic strategies to treat Chagas disease. In this study, a hypothetical open reading frame (ORF) for NMNAT was identified in the genome of T. cruzi.The corresponding putative protein was analysed by simulating structural models. The ORF was amplified from genomic DNA by polymerase chain reaction and was further used for the construction of a corresponding recombinant expression vector. The expressed recombinant protein was partially purified and its activity was evaluated using enzymatic assays. These results comprise the first identification of an NMNAT in T. cruzi using bioinformatics and experimental tools and hence represent the first step to understanding NAD+ metabolism in these parasites.

Identification of the nicotinamide mononucleotide adenylyltransferase of Trypanosoma cruzi

The intracellular parasite Trypanosomacruzi is the aetiological agent of Chagas disease, a public health concern with an increasing incidence rate. This increase is due, among other reasons, to the parasite’s drug resistance mechanisms, which require nicotinamide adenine dinucleotide (NAD+). Furthermore, this molecule is involved in metabolic and intracellular signalling processes necessary for the survival of T. cruzithroughout its life cycle. NAD+biosynthesis is performed by de novo and salvage pathways, which converge on the step that is catalysed by the enzyme nicotinamide mononucleotide adenylyltransferase (NMNAT) (enzyme commission number: 2.7.7.1). The identification of the NMNAT of T. cruziis important for the development of future therapeutic strategies to treat Chagas disease. In this study, a hypothetical open reading frame (ORF) for NMNAT was identified in the genome of T. cruzi.The corresponding putative protein was analysed by simulating structural models. The ORF was amplified from genomic DNA by polymerase chain reaction and was further used for the construction of a corresponding recombinant expression vector. The expressed recombinant protein was partially purified and its activity was evaluated using enzymatic assays. These results comprise the first identification of an NMNAT in T. cruziusing bioinformatics and experimental tools and hence represent the first step to understanding NAD+ metabolism in these parasites.

Identification and functional evaluation of Leishmania braziliensis Nicotinamide Mononucleotide Adenylyltransferase.

The progressive increase in Leishmania resistance to current control approaches prompts the need to develop therapeutic strategies based on comprehensive knowledge of the parasite's biology. The enzyme Nicotinamide Mononucleotide Adenylyltransferase (NMNAT, EC 2.7.7.1) catalyzes the central step in nicotinamide adenine dinucleotide (NAD(+)) biosynthesis, making it essential for the survival of all organisms. NAD(+) metabolism is related to the maintenance of several biochemical, cellular, and physiological processes; consequently, the characterization and analysis of the enzymes involved in its biosynthesis represent key steps in the development of control strategies. In this study, the NMNAT enzymes of different Leishmania species were identified using bioinformatics procedures. The sequences were used to construct structural homology models that revealed characteristic elements common to NMNATs. The open reading frame of Leishmania braziliensis NMNAT was cloned from complementary DNA and the enzymatic activity of the corresponding recombinant protein was confirmed through enzymatic assays. Primary structure analysis revealed a Leishmania-specific amino-terminal insertion in NMNAT. The deletion of this insertion is negatively correlated with in vitro enzymatic activity. From our observations, we suggest the amino-terminal insertion of Leishmania NMNATs as a promising pharmacological target for the development of specific control strategies.

DISEÑO Y PRODUCCIÓN DE UNA HERRAMIENTA MOLECULAR PARA EL ESTUDIO DEL N-TERMINAL DE LA NICOTINAMIDA MONONUCLEÓTIDO ADENILIL TRANSFERASA (NMNAT) EN Leishmania braziliensis / DESIGN AND PRODUCTION OF A MOLECULAR TOOL TO STUDY OF N-TERMINAL NICOTINAMIDE MONONUCLEOTIDE ADENYLYL TRANSFERASE (NMNAT) IN Leishmania braziliensis / DESIGN E PRODUÇÃO DE UMA FERRAMENTA MOLECULAR PARA O ESTUDO DO TERMINALN DA NICOTINAMIDA CICLASE MONONUCLEÓTIDO TRANSFERASE (NMNAT) EM Leishmania braziliensis

Leishmania braziliensis es un parásito protozoario causante de la mayor parte de casos de leishmaniasis cutánea en al menos quince países del continente americano. La Organización Mundial de la Salud (OMS) ha reportado que cerca de doce millones de personas están infectadas en el mundo y que este número aumenta cada año. Debido al delicado problema de salud pública derivado de la prevalencia de esta enfermedad se hace necesario el estudio del metabolismo de este parásito. En tal sentido se ha estudiado la proteína NMNAT de este parásito, la cual es una enzima central del metabolismo de todos los organismos al estar encargada de la síntesis del NAD+, un importante cofactor en reacciones redox de procesos centrales del metabolismo celular. En la NMNAT de L. braziliensis se ha encontrado una secuencia de 44 aminoácidos en el extremo N-terminal carente de homología con la proteína del hospedero. En este estudio se produjeron anticuerpos IgG específicos contra esta secuencia, utilizando como antígenos péptidos que contuvieran la secuencia mencionada. Los anticuerpos obtenidos mostraron un reconocimiento de la NMNAT recombinante de L. braziliensis mediante ensayo por western blot.

Leishmania braziliensis is a protozoan which is cause of the most of the cutaneous leishmaniasis cases in at least 15 countries from America. World Health Organization (WHO) has reported that around 12 millions of people are infected in the world and this number increase every year. Because of the delicate problem of public health due to the prevalence of this disease, it is necessary the metabolism study in this parasite. In this way has been studied NMNAT protein of the parasite, which is a central enzyme of the metabolism of all organisms, since it is in charge of synthesizing NAD+, an important cofactor in oxidation-reduction reactions of central processes in the cellular metabolism. In The NMNAT of L. has been found a 43 amino acids sequence in the N terminal, which does not have homology with the protein in the human host. In this study were produced IgG antibodies against this sequence, using like antigens peptides that had the mentioned sequence. The produced antibodies recognized the recombinant NMNAT of L. braziliensis through western blot assay.

Leishmania braziliensis é um parasita protozoário que causa a maioria dos casos de leishmaniose cutânea em pelo menos 15 países das Américas. A Organização Mundial de Saúde (OMS) informou que cerca de 12 milhões de pessoas estão infectadas em todo o mundo e esse número aumenta a cada ano. Devido ao delicado problema de saúde pública decorrentes da prevalência desta doença é necessário estudar o metabolismo do parasita. A este respeito temos estudado a proteína NMNAT deste parasita, que é uma enzima central no metabolismo de todos os organismos de estar envolvido na produção de NAD+, um importante cofator em reações redox de processos centrais de celulares metabolismo. No L. braziliensis NMNAT encontrou uma seqüencia de 43 aminoácidos no terminal N homologia com a proteína faltando host. Este estudo produziu anticorpos IgG específicos para esta seqüência, usando como peptídeos de antígeno contendo a seqüência mencionada. Os anticorpos obtidos mostraram um reconhecimento da NMNAT L. braziliensis recombinantes por meio de julgamento por western blot.